Cargando…
Prediction of Sensitivity to STI571 among Chronic Myeloid Leukemia Patients by Genome‐wide cDNA Microarray Analysis
One of the most critical issues to be solved in regard to cancer chemotherapy is the establishment of ways to predict the efficacy of anti‐cancer drugs for individual patients. To develop a prediction system based on expression of specific genes, we analyzed expression profiles of mononuclear cells...
Autores principales: | Kaneta, Yasuyuki, Kagami, Yoshitoyo, Katagiri, Toyomasa, Tsunoda, Tatsuhiko, Jin‐nai, Itsuro, Taguchi, Hirokuni, Hirai, Hisamaru, Ohnishi, Kazunori, Ueda, Takanori, Emi, Nobuhiko, Tomida, Akihiro, Tsuruo, Takashi, Nakamura, Yusuke, Ohno, Ryuzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927114/ https://www.ncbi.nlm.nih.gov/pubmed/12716460 http://dx.doi.org/10.1111/j.1349-7006.2002.tb01328.x |
Ejemplares similares
-
Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease
por: Re, D, et al.
Publicado: (2002) -
Effects of STI571 (gleevec) on pancreatic cancer cell growth
por: Li, Junsheng, et al.
Publicado: (2003) -
Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro
por: Zhang, Peilin, et al.
Publicado: (2003) -
Management of Skin Toxicity Related to the Use of Imatinib
Mesylate (STI571, Glivec™) for Advanced Stage Gastrointestinal
Stromal Tumours
por: Scott, Lucy C., et al.
Publicado: (2005) -
Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571)
por: Pinder, Elizabeth M., et al.
Publicado: (2007)